- Home
- Publications
- Publication Search
- Publication Details
Title
Investigation of FOXM1 as a Potential New Target for Melanoma
Authors
Keywords
Melanomas, Melanoma cells, Small interfering RNAs, Cancer immunotherapy, MAPK signaling cascades, Gene expression, Immunohistochemical analysis, Cell signaling
Journal
PLoS One
Volume 10, Issue 12, Pages e0144241
Publisher
Public Library of Science (PLoS)
Online
2015-12-09
DOI
10.1371/journal.pone.0144241
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet
- (2015) Grant A. McArthur Frontiers in Oncology
- The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA
- (2015) Ming Wang et al. Oncotarget
- Kinesin Family Member 20A is a Novel Melanoma-associated Antigen
- (2013) J Yamashita et al. ACTA DERMATO-VENEREOLOGICA
- FoxM1 is Overexpressed in Helicobacter pylori –Induced Gastric Carcinogenesis and Is Negatively Regulated by miR-370
- (2013) Yimin Feng et al. MOLECULAR CANCER RESEARCH
- Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells
- (2012) Caroline Bonet et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- FOXM1 Induces a Global Methylation Signature That Mimics the Cancer Epigenome in Head and Neck Squamous Cell Carcinoma
- (2012) Muy-Teck Teh et al. PLoS One
- BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
- (2012) Brenden Chen et al. PLoS One
- FoxM1: A Master Regulator of Tumor Metastasis
- (2011) P. Raychaudhuri et al. CANCER RESEARCH
- Expression of FoxM1 Is Required for the Proliferation of Medulloblastoma Cells and Indicates Worse Survival of Patients
- (2011) M. Priller et al. CLINICAL CANCER RESEARCH
- BRAFV600E: Implications for Carcinogenesis and Molecular Therapy
- (2011) E. R. Cantwell-Dorris et al. MOLECULAR CANCER THERAPEUTICS
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel anticancer compounds induce apoptosis in melanoma cells
- (2010) Uppoor G. Bhat et al. CELL CYCLE
- Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells
- (2010) Zhiwei Wang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells
- (2010) Kim Mai Huynh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- FoxM1, a critical regulator of oxidative stress during oncogenesis
- (2009) Hyun Jung Park et al. EMBO JOURNAL
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple Antigen-targeted Immunotherapy With α-Galactosylceramide–loaded and Genetically Engineered Dendritic Cells Derived From Embryonic Stem Cells
- (2009) Satoshi Fukushima et al. JOURNAL OF IMMUNOTHERAPY
- Thiazole Antibiotics Target FoxM1 and Induce Apoptosis in Human Cancer Cells
- (2009) Uppoor G. Bhat et al. PLoS One
- Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer
- (2008) Nuran Bektas et al. BMC CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started